

FOR IMMEDIATE RELEASE

July 20, 2016

**PLUROGEN THERAPEUTICS, LLC, ANNOUNCES ISSUANCE OF US PATENT
TO FIGHT BIOFILM IN WOUNDS**

Norristown, PA- PluroGen Therapeutics, LLC, a biotech company that provides clinically advanced topical products for chronic (non-healing) wounds and burns, today announced that the United States Patent and Trademark Office has issued US Patent #9,283,278 covering the company's PluroGel® Micelle Matrix Biomaterial to fight biofilm in wounds.

This new biofilm patent strengthens PluroGen's intellectual property portfolio of 9 current patents and 10 additional patent applications. The biofilm patent confirms the Company's strategic commitment in developing solutions for complex wounds that are useful for patients, doctors and healthcare providers.

"We are confident that PluroGen's extensive patent estate will continue to provide our company with long-term protection for our strategic focus in the burn and wound care market." said Neal Koller, President and CEO of PluroGen. *"This additional patent for fighting biofilm, thought to be one of the key reasons that nonhealing wounds do not heal, represents another significant milestone in securing comprehensive protection for the PluroGel Micelle Matrix line of products."*

Nonhealing wounds are responsible for a significant economic burden and an increase in morbidity and mortality for patients. Rates of clinical wound closure remain unacceptably low. One suspected reason for nonhealing wound closure is the presence of biofilm. Biofilm is a thin, slimy film of bacteria that adheres to a surface and are thought to physically block a wound from closing. A key characteristic of PluroGel is its bio-physical function of breaking up or preventing biofilm formation, which in turn, can aid in wound closure.

PluroGel is a unique, biocompatible, cell-friendly, surfactant-based biomaterial and is beneficial in all phases of wound healing and for all tissue types. Developed at the world-renowned University of Virginia, PluroGel Products give doctors, nurses, patients and consumers advantaged and cost effective new tools for skin, burn and wound care.

About PluroGen Therapeutics

PluroGen Therapeutics, LLC, is a burn, wound, and skin care company that develops, manufactures and markets its proprietary line of PluroGel® products. PluroGen's patent-protected technology is derived from the surfactant-based PluroGel Micelle Matrix (PMM) Biomaterial, providing physicians and patients with new, paradigm-shifting and superior products for burns and chronic wound care. PluroGel products offer Multi-Function advantages and have been routinely used worldwide with documented beneficial and clinically advanced results in patients.

Contact Information:

Lori Kavle
+1 (610) 539-3670
lkavle@plurogen.com
www.plurogen.com

Safe Harbor Statement:

The statements in the press release that relate to PluroGen's (the Company) expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.